產(chǎn)品描述: | BMH-21是一種DNA嵌入劑,與核糖體DNA結(jié)合,并抑制RNA polymerase I (Pol I)轉(zhuǎn)錄 |
靶點(diǎn): |
RNA polymerase I;DNA/RNASynthesis |
體外研究: |
BMH-21引起RPA194蛋白酶體依賴(lài)性破壞,RPA194為Pol I全復(fù)合物的大催化亞基蛋白。 在U2OS癌癥細(xì)胞系,BMH-21導(dǎo)致RPA194降解和NCL易位,IC50分別為0.05 μM 和 0.07 μM。通過(guò)引起核仁應(yīng)激,BMH-21對(duì)細(xì)胞活性也表現(xiàn)出有效的抑制 |
體內(nèi)研究: |
在小鼠異種移植物中,BMH-21降低腫瘤的生長(zhǎng) |
細(xì)胞實(shí)驗(yàn): |
Cell lines: U2OS 骨肉瘤細(xì)胞 Concentrations: ~5 μM Incubation Time: 48小時(shí) Method: 細(xì)胞在包含5% CO2的大氣中維持在37℃。U2OS骨肉瘤細(xì)胞在DMEM中培養(yǎng),用15%牛胎兒血清補(bǔ)充。細(xì)胞以10000細(xì)胞/孔的密度重復(fù)三份接種在96孔板,并與化合物培養(yǎng)48小時(shí)。活性使用WST-1細(xì)胞增殖試劑測(cè)定 |
動(dòng)物實(shí)驗(yàn): |
Animal Models: Athymic NCr nu/nu mice Dosages: 25 or 50 mg/kg Administration: i.p. |
參考文獻(xiàn): |
1. Peltonen K, et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell. 2014, 25(1), 77-90. 2. Colis L, et al. Design, synthesis, and structure-activity relationships of pyridoquinazolinecarboxamides as RNA polymerase I inhibitors.J Med Chem. 2014, 57(11), 4950-4961. 3. Peltonen K, et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell. 2014 Jan 13;25(1):77-90. |
溶解性: |
Soluble in DMSO、Ethanol |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
2.775 ml |
13.873 ml |
27.746 ml |
5 mM |
0.555 ml |
2.775 ml |
5.549 ml |
10 mM |
0.277 ml |
1.387 ml |
2.775 ml |
50 mM |
0.055 ml |
0.277 ml |
0.555 ml |
|
注意: |
部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶(hù)參考交流研究之用。 |